5ARI and PSA: Open Questions

    July 2014 in “ Urologia Journal
    Andrea Tubaro, Federica Puccini, Cosimo De Nunzio
    TLDR 5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.
    The document discussed the challenges and limitations of using serum prostate specific antigen (PSA) as a diagnostic tool for prostate cancer, particularly in the context of benign prostatic hyperplasia (BPH) and other factors that can elevate PSA levels. It highlighted that 5-alpha reductase inhibitors (5ARI), such as finasteride and dutasteride, used to treat BPH, significantly reduced PSA levels by about 50%. This reduction raised concerns about the reliability of PSA testing for early prostate cancer diagnosis in patients undergoing 5ARI treatment. However, analysis of clinical trial data suggested that PSA testing accuracy was not only maintained but improved with 5ARI use, effectively resolving concerns about PSA accuracy during such treatment.
    Discuss this study in the Community →

    Related Community Posts Join

    6 / 1000+ results

      community Update: 4 Month progress on Fin/Min plus dermaroller

      in Progress Pictures  559 upvotes 1 year ago
      A user shared a 4-month update on their hair regrowth progress using finasteride, minoxidil, a dermaroller, ketoconazole shampoo, multivitamins, and biotin, and received positive reactions and inquiries from others. They also mentioned lifestyle changes such as quitting creatine, alcohol, and smoking, which may have contributed to their success.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 1 year ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

    Related Research

    3 / 3 results